Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,176
  • Shares Outstanding, K 9,124
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,400 K
  • 60-Month Beta 3.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +140,804.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +0.40%
on 04/18/19
4.75 -46.55%
on 03/19/19
-1.86 (-42.27%)
since 03/18/19
3-Month
1.29 +96.90%
on 02/01/19
7.39 -65.63%
on 03/14/19
+1.20 (+89.55%)
since 01/18/19
52-Week
0.80 +217.50%
on 12/26/18
7.39 -65.63%
on 03/14/19
-1.78 (-41.20%)
since 04/18/18

Most Recent Stories

More News
New Research Coverage Highlights Thermon Group, Apogee Enterprises, National Research, Gulf Resources, Atossa Genetics, and Broadwind Energy -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Thermon Group Holdings, Inc....

GURE : 1.38 (-5.14%)
BWEN : 1.84 (+9.52%)
NRCIA : 33.55 (+1.51%)
APOG : 39.17 (-0.46%)
ATOS : 2.54 (-3.05%)
NRC : 38.99 (-0.38%)
THR : 26.16 (+1.04%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

AGEN : 2.53 (-0.39%)
OMED : 0.94 (-12.16%)
ATOS : 2.54 (-3.05%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0240 (unch)
SNSS : 1.15 (-4.96%)
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year...

ATOS : 2.54 (-3.05%)
Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.54 (-3.05%)
Estimated Revenues Continue to Rise for U.S. and Global Medical Device Markets

The U.S. medical device industry has seen its revenues continue to increase and it is poised is to become the global leader of this expanding market. It seems as though each new projection breaks through...

DERM : 11.55 (+3.77%)
ATOS : 2.54 (-3.05%)
BPTH : 19.02 (-5.93%)
AVGR : 0.59 (-6.96%)
SOLY : 11.89 (-9.99%)
Atossa Genetics Announces Receipt of $10 Million

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.54 (-3.05%)
Thinking about buying stock in Atossa Genetics Inc., Canopy Growth Corp., Facebook Inc., Micron Technology Inc., or Oxbridge Holdings?

InvestorsObserver issues critical PriceWatch Alerts for ATOS, CGC, FB, MU, and OXBR.

MU : 43.40 (+0.58%)
ATOS : 2.54 (-3.05%)
FB : 178.28 (-0.28%)
Atossa Genetics Announces FDA Approval of Oral Endoxifen for "Expanded Access" as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.54 (-3.05%)
Atossa Genetics Reports Results From "Expanded Access" Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

, February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other...

ATOS : 2.54 (-3.05%)
Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 2.54 (-3.05%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 2.72
1st Resistance Point 2.63
Last Price 2.54
1st Support Level 2.49
2nd Support Level 2.44

See More

52-Week High 7.39
Fibonacci 61.8% 4.87
Fibonacci 50% 4.09
Fibonacci 38.2% 3.32
Last Price 2.54
52-Week Low 0.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar